Percepta for cognitive optimization in adults with mild cognitive impairment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1, randomized, double-blind, placebo-controlled trial conducted in a decentralized format. Participants aged 40–85 with self-reported mild cognitive impairment will take either Percepta (750 mg daily) or a matched placebo for 6 months, with an optional extension to 12 months. Primary outcome is changes in cognitive performance measured by digital MoCA at baseline, 3 months, and 6 months. Secondary outcomes include sleep and autonomic metrics from Oura Ring wearables and Brain Health Index scores; an exploratory sub-study will assess plasma pTau-217 as a potential mechanism. The study leverages remote monitoring and at-home assessments to evaluate safety, tolerability, and signal of cognitive benefit from a plant-based supplement containing cat's claw bark extract and oolong tea extract.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Demographics: Must be English-speaking and currently residing in the United States.
* Cognitive Status: Must have self-reported cognitive impairment, defined specifically by a Montreal Cognitive Assessment (MoCA) score of less than 25.
* Technology Access: Must own an Oura Ring, maintain an active membership throughout the study, and have consistent access to a smartphone for app-based surveys and data syncing.
* Medical Stability: Must be in good general health and medically stable, with no significant health changes in the three months prior to enrollment.
* Consent and Compliance: Must provide signed informed consent and demonstrate a willingness to comply with all study procedures, including assessments and lifestyle considerations.

Exclusion Criteria:

* Neurological and Psychiatric Disorders: A self-reported diagnosis of dementia, Alzheimer's disease, Parkinson's disease, depressive disorders, bipolar disorder, schizophrenia, epilepsy, multiple sclerosis, or substance use disorder. This also includes a history of stroke, traumatic brain injury (TBI), intracranial hemorrhage, or seizure disorders.
* Medication Use: Current use of cognitive-affecting medications or supplements, such as donepezil, memantine, methylphenidate, benzodiazepines, antipsychotics, or nootropics.
* Allergies: Known allergy or sensitivity to cat's claw or oolong tea,. Reproductive Status: Currently pregnant, breastfeeding, or planning to become pregnant within the next 12 months.
* Genetic Risk: Known carrier of the APOE-4 allele.
* Recent Study Participation: Enrollment in another clinical trial or intervention study within the past 30 days.

Where it's running

• Reputable Health
  Wilmington, Delaware, United States Recruiting

Study contacts

• Study coordinator: Mackenzie De Jesus, DHSc, MS
• Email: mackenzie@reputable.health
• Phone: 754-301-9531

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rural Veterans and Care Partners Walking Program

  A virtual walking program is tested to see if it can help Veterans with mild cognitive impairment and their care partners in rural areas walk more each day.

  Recruiting Creighton University · Omaha, Nebraska · NCT07914218

• China HEAD: a large community study on healthy aging and dementia

  This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.

  Recruiting at 30 sites Fudan University · Beijing and 29 other locations · NCT07912710

• Aging Brain Health Initiative in Fujian

  This observational study will follow about 3,000 older adults in Fujian to see how Alzheimer's-related changes develop and to test new digital tests, biomarkers, and imaging tools for early diagnosis.

  Recruiting at 4 sites Fujian Medical University Union Hospital · Fushun, Fujian and 3 other locations · NCT07891429

• See if multimodal biomarkers can map changes from mild cognitive impairment to dementia

  This observational study tests whether clinical, blood, and brain-imaging markers can tell apart stages of cognitive decline and predict progression from mild cognitive impairment to dementia in about 600 people.

  Recruiting Xuanwu Hospital, Beijing · Beijing, Beijing Municipality · NCT07876570

• LIFU to Help Sleep and Amyloid Reduction in Older Adults with Cognitive Impairment

  A wearable ultrasound device (ATTN201) is being tested to see if it’s safe and easy to use for people 65 and older with mild cognitive impairment and amyloid buildup.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07866768

• Digital STEADI: A home-based digital fall prevention program for older adults

  A home-based digital program using AI-driven conversational agents tests if a guided fall-prevention exercise plan can reduce fall risk for older adults with mild cognitive impairment living independently.

  Recruiting Phase 1/2 Friendi.fi Corporation · Atlanta, Georgia · NCT07852650

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.